Ulcerative Colitis Suppliers Serving Mongolia
8 companies found
based inConcord, MASSACHUSETTS (USA)
At Adiso, we create medicines to treat inflammatory diseases, improving the lives of patients and their families. Current treatment paradigms are far too often either inadequate to halt disease progression or burden the patient with significant ...
ADS024 is an oral single strain live biotherapeutic product (SS-LBP). A naturally occurring live biotherapeutic product, ADS024 modulates inflammation as a single strain multimodal LBP and has been shown to reduce neutrophil trafficking ...
based inBellinzona, SWITZERLAND
MV Biotherapeutics (MV Bio) is a early stage Swiss biotherapeutics company, and a spin-off from the Institute for Research in Biomedicine (IRB) in Bellinzona, Switzerland. MV Bio is developing first-in-class mucosal immune enhancers for the ...
SNP-apyrase for oral use in the treatment of IBD • Lead compound, MV010, has shown animal PoC in a murine model of ulcerative colitis. • Abrogation of the pro-inflammatory function of extracellular ATP in the intestine without systemic immune ...
based inLondon, UNITED KINGDOM
At Benevolent we build technology in the service of science - to augment human intelligence and inspire the discovery of new medicines for the thousands of diseases that have no treatment. Building the right team is an art not a science. We strive ...
Better target discovery and compound design in Ulcerative Colitis. What is UC?: Ulcerative colitis (UC) is a chronic, lifelong disease that causes inflammation and ulceration of the inner lining of the colon and rectum, accompanied by debilitating ...
based inGwanak-ro, Gwanak-gu, SOUTH KOREA
KoBioLabs is recognized for its international level of technical skills by publishing a number of domestic and foreign patent papers in the fields of microbiome analysis, probiotics, and microbiome treatment technologies of various samples. In ...
based inMechelen, BELGIUM
Galapagos discovers, develops and commercializes small molecule medicines with novel modes of action. Our pipeline comprises discovery through to Phase 3 programs in inflammation, fibrosis, and other indications. Our first medicine is approved and ...
Filgotinib, a preferential JAK1 inhibitor, is marketed as Jyseleca in the European Union (incl. Norway), Great Britain, and Japan for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have responded ...
based inOsaka, JAPAN
Alfresa Pharma develops, manufactures, and sells diagnostic reagents and equipments used in hospital laboratories and group medical examinations, with the mission of “delivering unprecedented new in vitro diagnostics.” We have applied our original ...
The conventional fecal calprotectin test often uses the ELISA method. However, our NESCAUTO® Cp Auto products use a colloidal gold agglutination method, which is an immunoassay. The gold colloid agglutination method optically measures the color ...
based inSomerville, MASSACHUSETTS (USA)
Finch Therapeutics is a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel class of orally administered biological drugs. With the capabilities to develop both complete and targeted ...
In collaboration with Takeda Pharmaceuticals, we are developing FIN-524 and FIN-525, orally administered, Targeted Consortia product candidates designed for the treatment of ulcerative colitis (UC) and Crohn’s disease (CD), respectively. UC ...
based inParis, FRANCE
Abivax develops innovative treatments modulating the body’s natural immune system machinery to treat patients with chronic inflammatory diseases, viral infections and cancer. As a clinical-stage company, Abivax leverages its immune enhancing and ...
ABX464 is an oral, first-in-class, small molecule that has demonstrated safety and profound anti-inflammatory activity in preclinical trials and in Phase 2a and Phase 2b induction trials to treat ulcerative colitis (UC). Patients who completed the ...